RxDoctor Payments Data

Scott McAllister, MD

Internal Medicine · Titusville, PANPI 1598757338

Payments from drug & device makers

$10,158in general payments, 2019–2025

Across 686 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Pfizer$1K
  • AbbVie$836
  • Merck$829
  • AstraZeneca$709
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,137100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,158 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,452
Medicare patients
68
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$162,376
XareltoRivaroxaban119$102,149
JardianceEmpagliflozin97$91,269
OzempicSemaglutide70$74,383
EntrestoSacubitril/Valsartan49$52,478
TrulicityDulaglutide31$30,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$25,784
FarxigaDapagliflozin Propanediol14$21,769
MyrbetriqMirabegron36$18,427
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$16,074
JanuviaSitagliptin Phosphate11$14,191
Breo ElliptaFluticasone/Vilanterol25$10,282
Repatha SureclickEvolocumab14$7,154
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,522
Insulin Lispro Kwikpen U-100Insulin Lispro13$3,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,152$163,805188 claims
Johnson & JohnsonXarelto$109$102,149119 claims
Boehringer IngelheimJardiance$1,198$91,26997 claims
Novo NordiskOzempic$1,260$74,38370 claims
NovartisEntresto$451$52,47849 claims
GSKTrelegy Ellipta, Breo Ellipta$524$36,06564 claims
Lilly USA, LLCTrulicity$593$30,09431 claims
AstraZenecaFarxiga$709$21,76914 claims
Astellas Pharma US IncMyrbetriq$52$18,42736 claims
MerckJanuvia$829$14,19111 claims
AbbVieSynthroid$836$1,50620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Titusville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →